Most Recent

Later-Line Infigratinib Outperforms Standard Chemotherapy in Cholangiocarcinoma

July 3rd 2020

By Rachel Narozniak, MA

Infigratinib conferred a clinically meaningful progression-free survival and overall response rate benefit when administered as a third- and later-line treatment for patients with FGFR2 fusion–positive cholangiocarcinoma.

Wainberg Weighs in on Favorable Frontline Activity With NALIRIFOX Regimen in Pancreatic Cancer

July 3rd 2020

By Jessica Hergert

Zev. A. Wainberg, MD, discusses findings from a phase 1/2 study of NALIRIFOX in patients with pancreatic ductal adenocarcinoma.

EDP1503 With or Without Pembrolizumab Has Clinical Activity Across Solid Tumors

July 3rd 2020

By Rachel Narozniak, MA

EDP1503, an investigational monoclonal microbial product, was safe and well-tolerated when administered in combination with pembrolizumab (Keytruda), and mechanistically drove some of the patient responses seen in a phase 1/2 study.

Brahmer Highlights Practice-Changing Data in HER2-Mutated NSCLC

July 3rd 2020

By Brittany Cote

Julie R. Brahmer, MD, discusses the details of the DESTINY-Lung01 trial, as well as remaining questions that could be answered with further research.

Irinotecan Monotherapy Shows Similar Activity, Improved Safety as Chemo Combo in Advanced Gallbladder Cancer

July 2nd 2020

By Caroline Seymour

Irinotecan monotherapy demonstrated similar clinical activity and improved safety compared with capecitabine plus irinotecan in patients with advanced gallbladder cancer, representing a potential second-line treatment for frail patients.

Latest Videos

All Content